Clinical Trial Update: Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating APL-1202 in combination with epirubicin versus epirubicin alone in chemo-refractory non-muscle invasive bladder cancer; current status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• APL-1202 (APL-1202)
• Epirubicin hydrochloride (epirubicin hydrochloride)

Snippet

Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris | Conditions: Non-muscle Invasive Bladder Cancer | Phase 3 | Status: UNKNOWN